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Objective: To inform health care providers about quality standards for manufacture of
probiotic products being recommended for at-risk patient populations.
Summary: Probiotics areused in avarietyof clinical settings, sometimes inat-riskpopulations for
therapeutic endpoints. Although probiotics might not be approved as drugs, they are sometimes
used for the prevention or treatment of disease. In the United States, and many regions of the
world, probiotic products are marketed as dietary supplements (not drugs) and are therefore
subject to differentmanufacturing andquality control standards than approveddrugs are. Health
care providers need to be assured that probiotic products used in at-risk populations are safe for
this use. Pharmacists should require certiﬁcates of analysis, which document quality standards,
frommanufacturers of products stocked in hospital formularies or other pharmacies dispensing
to at-risk people. Although responsible manufacturers use stringent quality standards on their
processes andﬁnishedproducts, using a third party toverify compliancewithmanufacturing and
accuracy of product labeling adds assurance to end users that the product is of high quality.
Conclusion: It is in patients’ best interest to use probiotics in the prevention and treatment of
conditions when the evidence is convincing. To protect high-risk patients, probiotic products
should meet stringent microbiological standards. Product testing results should be available
for review before recommending probiotic products to at-risk individuals. For products used in
at-risk populations, manufacturers should provide this information or participate in a third-
party veriﬁcation program that certiﬁes compliance.
© 2016 American Pharmacists Association®. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).cientiﬁc Ofﬁcer of UAS
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ation®. Published by ElsevieProbiotics are live microorganisms that, when adminis-
tered in adequate amounts, confer a health beneﬁt on the
host.1 Although probiotics are often not approved as drugs,
they are sometimes used for the prevention or treatment of
disease.2 As opportunities for clinical use for probiotics
expand, it is prudent to consider whether quality-control
standards established for the production of probiotics as
foods or dietary supplements are adequate to ensure safe,
clinical use in at-risk populations. Recently, a probiotic dietary
supplement comprising Biﬁdobacterium animalis subsp. lactis,
Streptococcus thermophilus, and Lactobacillus rhamnosus was
administered to a premature infant who subsequently died
from an infection caused by the opportunistic pathogen,
Rhizopus oryzae. Vallabhaneni et al.3 reported that this species
of mold was recovered from unopened bottles of the probiotic
supplement and from cecal tissue from the infant. The prob-
ability that this mold was a contaminant of the probiotic
product led us to consider microbiological standards for
probiotic products used for at-risk populations. Product
contamination can occur even in the most carefully controlled
processes, yet this incident highlights the need forr Inc. This is an open access article under the CC BY-NC-ND license (http://
Key Points
Background:
 Probiotics, although typically not sold as drugs, are
sometimes used by hospitalized or other at-risk
people.
Findings:
 Pharmacists should be aware of product quality
when recommending probiotic dietary supplements
for at-risk populations.
 Probiotic product manufacturers should, if asked,
provide evidence of quality criteria and inform
pharmacists on safe use of specific products in at-risk
populations.
 Probiotic product manufacturers can increase confi-
dence in safety of probiotic products through
involvement in programs that provide third-party
verification of quality.
Probiotics for at-risk populations
SCIENCE AND PRACTICEmanufacturers to establish, and adhere to, adequate quality
standards for probiotic products used for at-risk populations.
More stringent quality standards, compared with those
intended for the general population, may be needed. Examples
of at-risk subjects can include newborns (especially prema-
ture), patients requiring critical care, and people with a
weakened immune system, such as those with AIDS or on
immunosuppressant therapy.
For example, consider the use of probiotics in premature,
low-birth-weight infants at risk of developing necrotizing
enterocolitis (NEC). This population is characterized by a naive
immune system and aberrant gut microbial colonization.
A systematic review of 24 clinical trials comprising >5000
premature infants assessed the safety and effectiveness of
probiotics (i.e., Lactobacillus sp., Biﬁdobacterium sp., and
Saccharomyces cerevisiae var. boulardii) for the prevention of
NEC. In addition to ﬁnding efﬁcacy at preventing morbidity
and mortality associated with NEC, this review found no
reports of systemic infection with the supplemental probiotic
organisms used in the intervention.4 Commenting on this
Cochrane review, the editor-in-chief for Evidence-Based Child
Health concluded that, regarding probiotic use, “the concern in
extremely low birth weight infants has shifted from safety to
efﬁcacy” and “further studies are required only to compare
different formulations, doses and schedules.”5 This statement
supports the safe use of probiotics in this at-risk population.
However, safety of the product also requires sufﬁcient
manufacturing quality standards in products for such at-risk
subjects. Companies targeting such at-risk subjects (through
research or marketing, either formal or informal) may need to
conduct additional quality control measures and testing
beyond the typical standards.
It is important to distinguish between safety concerns
associated with the microbiological quality of probiotic prod-
ucts and probiotic safety per se. Our intent is not to review
probiotic safety, considering that much has already been
written and many processes are in place for assessing thesafety of probiotics for different uses (Table 1). An overview of
probiotic safety concluded that probiotics were safe for use in
otherwise healthy persons.15 This conclusion is reinforced by
the European Food Safety Authority, which considers all
common species of probiotics as safe for the general popula-
tion.9 The U.S. Food and Drug Administration (FDA) operates
on a case-by-case basis, but numerous probiotics have been
deemed generally recommended as safe for food use.6 Health
Canada has assessed documentation of safety for many pro-
biotics used as Natural Health Products and deemed them safe.
Considering the widespread consumption of probiotics, in-
fections linked to probiotics are rare.16 Reported adverse in-
cidents in clinical trials with probiotics are typically not
product-related, although reporting has lacked consistency
and thoroughness.17,18 Reports of infections by common pro-
biotic genera or species are almost exclusively limited to
immunocompromised individuals. However, rarely have the
microbes isolated from the infection been conﬁrmed to be the
same strain as the administered probiotic organism.19 Reports
often have not eliminated native or environmental sources of
similar species as the cause of the infection. Here, we turn our
focus to the microbiological quality of existing probiotic
products, with the presumption that safety of the probiotic
strain has been suitably assessed for the given use.
Objectives
Our objective in this commentary is to inform health care
providers about quality standards for the manufacture of
probiotic products being recommended for at-risk patient
populations. To the extent that the strength of evidence is
convincing for certain clinical uses of probiotics, such uses
should be encouraged as long as safety can be assured.
In particular, we focus this article on the control of
contaminating microbes through manufacturing quality
standards that are both reasonable and appropriate for com-
mercial probiotic products. We assume for the purposes of this
article that manufacturers have correctly identiﬁed the pro-
biotic strains contained in their product using current
phenotypic and genotypic methods (including genomic
sequencing) and have used correct nomenclature to describe
them. We limit our discussion to products containing only
probiotics and not those that contain other potentially func-
tional ingredients. Such standards must take into account that
probiotics by deﬁnition are not sterile; therefore, high levels of
live microbes will be (and should be) present in the ﬁnal
product. Although probiotics are delivered in conventional
foods, dietary supplements, and pharma products, we limit
our discussion to those delivered as dietary supplements,
natural health products, or other such non-food and non-drug
formulations. Furthermore, we will not address nonmicrobial
contamination concerns, such as allergens, various toxins, and
heavy metals. We also will not address the microbiological
quality issue of probiotic viability loss during handling after
production and product storage, as this important topic has
been addressed elsewhere.20,21
Experience from established standards and programs,
such as the United States Pharmacopeial Convention (USP),
NSF International (note that NSF is not an abbreviation),
Health Canada’s Natural and Non-Prescription Health Prod-
ucts Directorate, the Therapeutic Goods Association of681
Table 1
Safety assessment approaches for non-drug probiotic products
Safety assessment approach Geographic region Applicable to Description Reference
GRAS United States Foods, medical foods Can be self-afﬁrmed and kept conﬁdential,
or it can be submitted to the FDA for review
as a GRAS notiﬁcation
6,7
New dietary ingredient
notiﬁcation
United States New dietary ingredients
used in dietary supplements
Requires manufacturer or distributor to
provide the FDA, no later than 75 days prior
to marketing, the basis for the conclusion
that a dietary supplement containing a new
dietary ingredient is reasonably expected to
be safe under the conditions of use; must be
submitted 75 days prior to marketing
8
QPS European Union Foods List of microorganisms that do not require
speciﬁc safety testing for use in food
products,a with the exception of
documenting that strains of species on the
list do not carry transferable antibiotic
resistance
9
International Dairy Federation
list of safe microbes in dairy
products
International Foods Documents the history of use of live
microbes in foods
10
GMO regulation European Union Genetically modiﬁed
bacteria
Extensive safety testing required unless the
product is supported by a food authority of
an E.U. member state and no-objection is
waged by the European Commission or
other member states
11
Novel food regulation European Union Genetically modiﬁed bacteria
New probiotic species
Extensive safety testing required unless the
product is supported by a food authority of
an E.U. member state and no-objection is
waged by the European Commission or
other member states
12
Natural and Non-Prescription
Health Products Directorate
Canada Natural Health Products Product license issued by Health Canada
when appropriate GMPs, safety, and
efﬁcacy data are provided.
13
USP Global Dietary supplements Third-party veriﬁcation organization 14
Abbreviations used: GRAS, generally recognized as safe; FDA, U.S. Food and Drug Administration; GMO, genetically modiﬁed organism; E.U., European Union;
GMP, good manufacturing process; USP, United States Pharmacopeial Convention; QPS, Qualiﬁed Presumption of Safety.
a The European Food and Safety Authority (EFSA) is requested to assess the safety of a broad range of biological agents in the context of notiﬁcations for market
authorization as sources of food and feed additives, enzymes, and plant protection products. The QPS assessment was developed to provide a harmonized generic
preassessment to support safety risk assessments performed by EFSA’s scientiﬁc panels. The safety of unambiguously deﬁned biological agents (at the highest
taxonomic unit appropriate for the purpose for which an application is intended), and the completeness of the body of knowledge are assessed. Identiﬁed safety
concerns for a taxonomic unit are, where possible and reasonable in number, reﬂected as “qualiﬁcations” in connection with a recommendation for a QPS status.
The list of QPS recommended biological agents is reviewed and updated periodically.
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SCIENCE AND PRACTICEAustralia, and the FDA’s Center for Biologics Evaluation and
Research were considered. Recommendations are provided
for hospital and community pharmacies to guide decisions
on quality standards focused on microbiological contamina-
tion of probiotic products. We hope to heighten awareness
about probiotic product safety for at-risk populations among
stakeholders, including health care providers, pharmacists,
and industry quality specialists.
Regulatory categories for probiotic products
The importance of the regulatory category of probiotic
products might not be obvious to the end user. Probiotics are
delivered through foods, dietary or nutritional supplements,
drugs, infant formula, natural health products, foods for special
dietary uses, medical foods, and even devices. It is important to
recognize that different safety requirements exist for each
product category in various geographical jurisdictions. Most
important for this discussion is the difference in requirements
for dietary or nutritional supplements versus drugs. Whereas
premarket approval of safety is required for drugs, this might
not be the case for dietary or nutritional supplements. In the682United States, for example, dietary supplements, although in
pill or capsule form, are not required to meet the same
manufacturing and quality control standards as drugs.
The historic use of live microbes in foods and traditional
medicine has led to the current circumstance that probiotics
are most commonly associated with conventional foods,
dietary and nutritional supplements, and foods for special
dietary uses. Conventional foods and dietary and nutritional
supplements are products designed for the general popula-
tion. Because these products are not intended for at-risk
populations, it is not required to substantiate safety in these
populations. However, probiotics have been studied and used
clinically for therapeutic effects in at-risk human subjects.
The juxtaposition of these 2 realitiesdthe existence of
literature that supports therapeutic use of probiotics in
at-risk populations and that probiotics are commonly mar-
keted as foods and supplements for the general pop-
ulationdleads to the situation in which products can be used
in at-risk populations. Another complicating factor is that
health care providers often erroneously assume that all
probiotic strains or products are the same. This assumption
can lead to the use of a clinically undocumented product that
Probiotics for at-risk populations
SCIENCE AND PRACTICEmight not have been tested in or manufactured for an at-risk
patient population.Industry approach to the control of microbiological
contamination in probiotic products
Probiotic manufacturers are responsible for ensuring that
their products are safe and suitable for the intended consumer.
In the United States, the production of products containing
probiotics is regulated by the FDA under the appropriate good
manufacturing practices (GMPs) for food (21 CFR 110) and
dietary supplements (21 CFR 111). The GMP requirements for
food are currently being updated via a ﬁnal rulewith staggered
implementation through 2017 based on company size. It is
important to understand that GMPs do not specify what
testing needs to be done to assure microbiological purity.
Rather, they state that appropriate speciﬁcations for the limits
of contamination or prevention of “objectionable” microor-
ganisms must be established and that reliable testing pro-
cedures be followed. The manufacturer is responsible for
identifying microorganisms that are objectionable; this
determination is based on the contamination risk and the
intended consuming population. The criteria can be informed
by organizations such as NSF International22 and United States
Pharmacopeial Convention14 as well as by regulatory agencies.
Dietary supplements are not required to undergo
premarket approval in the United States; therefore, it is difﬁ-
cult for consumers or health care providers to know whether
probiotic products meet quality standards for pathogen risk
and product contents. Companies may elect to use a third-
party veriﬁcation program. For example, the USP offers a
Dietary Supplement Veriﬁcation program that includes a “USP
Veriﬁed” seal for the ﬁnished product label. This seal com-
municates that the supplement: contains the ingredients listed
on the label, in the declared strength and amounts; does not
contain harmful levels of speciﬁed contaminants; and is made
according to FDA and USP GMPs, using sanitary and well-
controlled processes. Monographs currently either in ﬁnal
form or in development by USP on several probiotics are
published in the Food Chemical Codex. The strains covered are
Bacillus coagulans GBI-39, 6086; Lactobacillus acidophilus
La-14; Lactobacillus acidophilusNCFM; Biﬁdobacterium animalis
subsp. lactis Bi-07; Biﬁdobacterium animalis subsp. lactis Bl-04;
B. animalis subsp. lactis HN019; Lactobacillus rhamnosus
HN001; and Lactobacillus paracasei Lpc-37.23 These mono-
graphs provide speciﬁcations formethods to identify the strain
level and quantify the strains, and can be used to develop third-
party veriﬁcation programs for dietary supplements.
In addition to the USP program, the Natural Products
Association24 offers a GMP program that certiﬁes adherence to
current GMPs for manufacturers of dietary supplements.
However, this process is less thorough than the USP veriﬁca-
tion program, which includes product testing and a chemistry,
manufacturing, and controls documentation review.
Any certiﬁcation program should be administered by an
established, reputable organization. Some companies include
seals on their products that are not associatedwithmeaningful
quality certiﬁcation. A product label stating that quality is
assured does not necessarily mean that the product under-
went rigorous third-party veriﬁcation.All natural health products sold in Canada must have a
product license issued by Health Canada. To obtain this license,
appropriate GMP must be followed, and proper safety and
efﬁcacy data consistent with the recommended conditions of
use must be provided for review and approval. Speciﬁc micro-
biological standards for at-risk populations are not speciﬁed in
guidance documents and the Natural and Non-prescription
Health Products Directorate typically applies limits to the
following organisms: total viable aerobic plate count, contam-
inating fungi (yeast andmold), Salmonella spp., Escherichia coli,
Staphylococcus aureus, and Pseudomonas aeruginosa (Table 2).
Mycotoxin testing is required for products containing ginseng
orpeanuts or any substancederived from these sources or other
selected products where fungal contamination is considered
likely. Tests for other pathogens (e.g., Listeria monocytogenes,
speciﬁc molds) are not typically conducted.
The nonsterile pharmaceutical microbiological contami-
nant testing standard described in the European Pharmaco-
peia is also summarized in Table 2. Note that the testing
requirements are almost identical to those in a natural health
product standard (Canada) and dietary supplement standard
(United States).
What do we recommend for a reasonable approach to
safe recommendation of probiotic products for at-risk
populations?
Good manufacturing practices
Companies marketing to an at-risk population may need to
conduct more rigorous testing than what is sufﬁcient for the
general population. Table 2 shows microbiological standards
recommended for probiotic products to be used for at-risk
populations. Hospital formularies should request that all
supplements on formulary have certiﬁcates of analysis that
document standards. Community pharmacists should
consider the same action when recommending products for
at-risk patients. Some of the required microbiological limits
are inappropriate for speciﬁc probiotic products (e.g., yeast
limits cannot apply to a probiotic comprising probiotic yeast)
and should be amended accordingly if safety can be assured.
Pathogen or toxin testing
Testing for speciﬁc pathogens or toxins might be needed if
the target group has a special vulnerability. For example,
pregnant women exposed to Listeria sp. are at risk of miscar-
riage. In addition, GMPs require that the manufacturer
consider the production process and deﬁne microbes of
concern. These concerns may differ among products,
depending on ingredients used.
Seek available guidance
Guidance regarding standards for safe use for at-risk pop-
ulations is available from some government authorities or
organizations (e.g., NSF International or USP). Manufacturers
targeting at-risk populations should apply available standards,
and pharmacists should verify that products are manufactured
using these standards.683
Table 2
Finished microbial impurity tests for products containing live microorganisms
Product Natural health
producta
Infant
formulasb
Dietary
supplementsc
Nonsterile
complementary
medicinesd
Nonsterile
productse
Nonsterile
products
Country Canada Canada U.S. Australia E.U. U.S.
Standards-issuing organization Health Canada Health
Canada
NSF Therapeutic Goods
Association
European
Pharmacopoeiaf
USP
Total aerobic count <104g <103 103 104
Yeast & mold <102h 102 102 102
Enterobacteriaceae and bile-tolerant
Gram-negative bacteria
<102i 102 102 102 <10 cfu/g
Salmonella species Absent, 10 g Absent Absent, 10 g Absent, 10 g or 10 mL Absent, 10 g Absent, 10 g
Escherichia coli Absent <1.8j Absent, 10 g Absent Absent Absent, 10 g
Staphylococcus aureus Absent <102 Absent, 10 g Absent Absent Absent, 10 g
Pseudomonas aeruginosa Absentk
Cronobacter sakazakii (formerly
Enterobacter sakazakii)
Absentl Absentm
Bacillus cereus <104
Clostridium perfringens <103 Absentn
Blank squares indicate that no standard is imposed. All values are CFU per gram or milliliter unless speciﬁed otherwise.
Abbreviations used: USP, United States Pharmacopeial Convention.
a Quality of Natural Health Products Guide, Natural and Non-Prescription Health Products Directorate. May 1, 2015. Version 3.1. Health Canada.
b Available at: http://www.hc-sc.gc.ca/fn-an/legislation/codes/infant_formula_gmp-eng.php#a0.4. Accessed August 9, 2016.
c NSF International Standard/American National Standard for Dietary Supplements. 2012. NSF/ANSI 173e2012. Published by NSF International, Ann Arbor, MI.
d Microbiological Quality of nonsterile pharmaceutical preparations and substances for pharmaceutical use. 2011. European Pharmacopoeia 7.0. Chapter 5.1.4.
e Not required for products containing facultative anaerobic microorganisms (that can live and grow with or without molecular oxygen).
f Not required for products containing fungal microorganisms.
g Could exceed the 102 CFU/g or CFU/mL limit for products containing nonmicrobial ingredients that have not undergone or have been subject to minimal
processing, such as an extraction, in which case a higher limit (or complete exclusion of testing) in line with an appropriate pharmacopeia (e.g., USP, British
Pharmacopoeia, or European Pharmacopoeia), would be considered acceptable.
h Testing required for liquid preparations only.
i Ph Eur provision for oral dosage forms containing raw materials of natural origin for which antimicrobial pretreatment is not feasible.
j The microbial attributes of a nonsterile medicine described in either section 9 of this Order or in the pharmacopoeias mentioned in this Order should not be
regarded as comprehensive microbial limit speciﬁcations. In addition to being free from the microorganisms speciﬁed in this Order, the sponsor must determine
the risk to the medicine from other objectionable microorganisms.
k Health Canada considers this opportunistic pathogen to be of concern for infants younger than 6 months, especially if conditions after reconstitution of infant
formula permit multiplication of the pathogen. The recommendation is that any sample testing positive for Enterobacteriaceae is tested for Cronobacter sakazakii,
and lots testing positive are rejected.
l This value was determined using a most probable number method.
m USP considers this opportunistic pathogen to be of concern for infants younger than 6 months of age.
n USP considers this opportunistic pathogen to be of concern for infants younger than 1 year of age.
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Conﬁdence in the safety that a probiotic product targeted to
at-risk populations is safe can be increased if the product is
subjected to a rigorous third-party veriﬁcation process. Such a
process should assure adherence to GMP standards, which
require sanitary and well-controlled processes, and contains
the ingredients listed on the label.
Be aware of potential contraindications
Probiotic products shouldbeusedwith caution for immune-
compromised patients, such as those with AIDS, lymphoma,
short bowel syndrome, or severe pancreatitis or those under-
going long-term corticosteroid treatment. The gut microbiota
was recently shown to affect drug uptake and disease treat-
ment efﬁcacy.25 It has not been shown that such a risk occurs
with probiotic use, but this may be a topic for future research.
Implications for pharmacists
Probiotics are increasingly being used clinically. Pharma-
cists may be asked to provide probiotics for consumers or
patients who are not fully healthy. Most probiotic products are684sold as dietary supplements, which are products categorized
for use in the general population. Probiotics should be man-
ufactured using high quality standards and (similar to any
medical intervention) should be safe from risk because of
microbiological contaminants. Pharmacists should work with
probiotic suppliers to ensure that probiotics that are stocked
or recommended can be veriﬁed to meet high-quality
manufacturing standards, such as those indicated in Table 2.
Furthermore, pharmacists should familiarize themselves with
published guidelines and other evidence-based recommen-
dations for probiotic use.
Conclusions
As with manufactured and well-studied drugs, supple-
ments have the potential to cause adverse events.26 Probiotics
are generally safe formost individuals.27 However, examples of
serious adverse events have been reported,28 and it is well-
accepted that septicemia is a theoretical risk of probiotic con-
sumption in some patients with serious underlying disease.
Nevertheless, probiotic products have been used safely in
preterm infants for the prevention of NEC,4 and inpatientswith
HIV,29,30 cancer,31 and other immunocompromised conditions.
Some have argued that only USP-certiﬁed supplements should
Probiotics for at-risk populations
SCIENCE AND PRACTICEbe provided in hospitals.32 Research and widespread use have
demonstrated the safe use of probiotics, but physicians, con-
sumers, and hospital systems need to be vigilant for potential
rare cases of adverse events. Patients, pharmacists, and other
health care providers should report any adverse incidents with
dietary supplements to the FDA, through their Dietary Sup-
plementseAdverse Event Reporting webpage.33 To improve
appropriate reporting of adverse incidents, researchers con-
ducting probiotic studies should report adverse events using
the Common Terminology Criteria for Adverse Events.17
For the best protection of high-risk patients, probiotic
products should meet microbiological standards such as those
presented in Table 2. Product testing results should be avail-
able for review before recommending probiotic products to
at-risk individuals. We recommend that for products used in
at-risk populations, manufacturers should provide this infor-
mation or participate in a third-party veriﬁcation program that
certiﬁes compliance.
The FDA requires that dietary supplements be manufac-
tured under GMPs, and currently there is no evidence that
probiotic dietary supplements in compliance with GMPs pose
a risk to the general population. Standards will adapt as new
testing is available and risks are identiﬁed. Many at-risk in-
dividuals are already known to consume probiotic products,
but the responsibility still falls on manufacturers, physicians,
and pharmacists to consider safe use for these individuals.Acknowledgments
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